Ganglioneuroma is a completely mature, benign neurogenic tumor arising from the peripheral sympathetic nervous system, representing the most benign end of the neuroblastic tumor maturation spectrum. Histologically, it contains mature ganglion cells, Schwann cells, and fibrous stroma with no neuroblastic component. It originates from the adrenal medulla or paravertebral sympathetic chain. Typically seen between ages 10-30 with slight female predominance. Most are asymptomatic and incidentally detected; catecholamine secretion is rare. On imaging, it appears as a well-defined, homogeneous, low-vascularity mass with delayed enhancement pattern. Risk of malignant transformation is negligible. Surgical resection is curative with no expected recurrence.
Age Range
10-40
Peak Age
25
Gender
Female predominant
Prevalence
Rare
Ganglioneuroma develops from neural crest-derived sympathoadrenal cells. These cells migrate from the neural crest during embryonic development to form the adrenal medulla and sympathetic ganglia. Ganglioneuroma is considered the fully matured final form of neuroblastoma — neuroblastoma can transform into ganglioneuroma through spontaneous maturation or after treatment. Histologically, it contains mature ganglion cells (large, with eosinophilic cytoplasm, prominent nucleoli) and Schwann cells (forming myxoid or fibrous stroma). The myxoid stroma formed by Schwann cells provides marked hyperintensity on T2-weighted MRI due to high water content — this is the most characteristic MRI finding of ganglioneuroma. The fibrous stroma component is responsible for delayed enhancement because contrast agent slowly diffuses into the fibrous interstitium. The tumor's low vascularity results from the mature Schwann cell stroma containing few vessels — hence arterial phase enhancement remains minimal. Calcifications are rare and fine-patterned in ganglioneuroma, reflecting that necrosis and dystrophic calcification are not expected because the tumor is benign and slow-growing.
The combination of a well-defined mass that is markedly homogeneous hyperintense on T2, non-enhancing in arterial phase but progressively mildly enhancing in delayed phase is near-pathognomonic for ganglioneuroma. This triad (homogeneous T2 hyperintensity + arterial minimal enhancement + delayed filling) reflects the myxoid composition and low vascularity of mature Schwann cell stroma.
On non-contrast CT, a well-defined, homogeneous, low-density (20-40 HU) mass is seen. The tumor is usually oval or fusiform in shape and grows without displacing surrounding structures — it may show an encasement growth pattern around vessels (without malignant invasion). Calcification is rare and when present appears as fine, punctate pattern. Necrosis or hemorrhage is not expected. Tumor size is variable ranging from 2-15 cm; well-defined margins are maintained despite large size.
Report Sentence
A well-defined, homogeneous, low-density mass is seen in the adrenal lodge/retroperitoneal space; no calcification or necrosis is observed; ganglioneuroma should be primarily considered.
On contrast-enhanced CT, minimal or no enhancement is seen in the arterial phase, while progressive mild enhancement is observed in the delayed phase (3-5 minutes). This delayed filling pattern is quite characteristic of ganglioneuroma. Enhancement is homogeneous and heterogeneity is not expected. The absence of arterial phase enhancement reflects the tumor's low vascularity. Delayed enhancement represents slow diffusion of contrast agent into the fibrous interstitium.
Report Sentence
The mass shows no enhancement in the arterial phase but demonstrates progressive mild homogeneous enhancement in the delayed phase; this delayed filling pattern is consistent with ganglioneuroma.
On T2-weighted MRI, ganglioneuroma demonstrates marked homogeneous hyperintense signal. This high signal reflects the high water content of the tumor's dominant myxoid Schwann cell stroma. Signal homogeneity results from the tumor's uniform histological composition (mature ganglion + Schwann stroma). Rarely, T2 hypointense fibrous bands may be seen within the tumor — described as 'whorled appearance'. Cystic or necrotic areas are not expected.
Report Sentence
The mass demonstrates marked homogeneous hyperintense signal on T2-weighted images consistent with myxoid Schwann cell stroma; ganglioneuroma should be primarily considered.
On T1-weighted images, ganglioneuroma shows homogeneous hypointense signal — lower signal than muscle and liver. This low T1 signal reflects the high water content of myxoid stroma. Hemorrhagic foci or T1 hyperintense areas are not expected; this homogeneous low signal is a supportive finding for benign neurogenic tumor.
Report Sentence
The mass demonstrates homogeneous hypointense signal on T1-weighted images without hemorrhagic or hyperintense components.
On diffusion-weighted imaging, ganglioneuroma does not show significant diffusion restriction. ADC values are high (typically 1.5-2.5 × 10⁻³ mm²/s) — reflecting low cellular density and the extracellular matrix not restricting water diffusion. This finding is valuable in differentiating from high-cellularity malignant tumors and clearly separates it from neuroblastoma (low ADC, high cellularity).
Report Sentence
The mass does not demonstrate significant diffusion restriction on diffusion-weighted images with high ADC values; this finding is consistent with a low-cellularity benign neurogenic tumor.
On I-123 or I-131 MIBG scintigraphy, ganglioneuroma shows no uptake. This results from mature ganglion cells completely losing norepinephrine transporter (NET) expression during differentiation. MIBG negativity is an important criterion distinguishing ganglioneuroma from neuroblastoma (positive uptake) and ganglioneuroblastoma (heterogeneous uptake).
Report Sentence
No uptake is observed in the adrenal lodge mass on MIBG scintigraphy; this negative MIBG finding is consistent with mature neurogenic tumor (ganglioneuroma).
Criteria
Composed entirely of mature ganglion cells and Schwann cell stroma. No neuroblastic component. Develops de novo or from spontaneous maturation of neuroblastoma.
Distinct Features
Most homogeneous form on imaging — smooth T2 hyperintensity, minimal delayed enhancement, rare calcification. Excellent prognosis, no expected recurrence.
Criteria
Predominantly contains mature ganglion cells but may also contain differentiating neuroblasts in the maturation process (no neuroblastic nidus). Schwann stroma dominant. Unlike intermixed ganglioneuroblastoma, no immature neuroblastic cell nests present.
Distinct Features
May be indistinguishable from mature ganglioneuroma on imaging. Minimal focal DWI restriction may be seen. MIBG negative or very faint uptake. Clinical behavior same as mature ganglioneuroma — surgery is curative.
Criteria
Coexistence of pheochromocytoma component within ganglioneuroma background. Very rare. Both components are histologically identifiable.
Distinct Features
On imaging, intensely enhancing T2 hyperintense focus within predominantly ganglioneuroma features. Catecholamine levels may be elevated (from pheochromocytoma component). MIBG may show focal uptake. Clinical management follows pheochromocytoma protocol (alpha-blockade).
Distinguishing Feature
Ganglioneuroblastoma shows heterogeneous T2 signal and enhancement; ganglioneuroma is homogeneous. DWI restriction may be positive in ganglioneuroblastoma, absent in ganglioneuroma. On MIBG, ganglioneuroblastoma shows heterogeneous uptake, ganglioneuroma shows none.
Distinguishing Feature
Schwannoma may also show T2 hyperintensity and delayed enhancement; however, schwannoma frequently becomes heterogeneous with cystic degeneration and hemorrhage. Schwannoma appears as fusiform mass related to nerve sheath while ganglioneuroma originates from adrenal medulla/sympathetic chain.
Distinguishing Feature
Adrenal cyst is a water-density (<20 HU), thin-walled, non-enhancing lesion; ganglioneuroma is a solid mass with delayed enhancement. On MRI, cyst is T1 hypointense/T2 very hyperintense (fluid signal) while ganglioneuroma is T2 hyperintense but not as high as fluid.
Distinguishing Feature
Pheochromocytoma shows intense arterial enhancement (ganglioneuroma does not enhance); very bright 'light bulb' T2 signal (may be brighter than ganglioneuroma). Pheochromocytoma associated with catecholamine elevation. On MIBG, pheochromocytoma shows intense uptake, ganglioneuroma shows none.
Urgency
routineManagement
surgicalBiopsy
Not NeededFollow-up
12-monthGanglioneuroma is a completely benign tumor with no risk of malignant transformation. Definitive diagnosis can be made with imaging findings (homogeneous T2 hyperintensity, delayed enhancement, MIBG negativity) and biopsy is generally not needed. Follow-up may be considered for asymptomatic small lesions (<4 cm). Surgical resection is curative for symptomatic or large lesions; no recurrence expected. Urine catecholamine levels are generally normal. Urgent surgery not needed if no functional syndrome. Association with MEN2 or neurofibromatosis type 1 should be investigated.
Ganglioneuroma is a benign tumor and is usually asymptomatic. Surgical resection is curative but partial resection is also acceptable. Differentiation from neuroblastoma is made histopathologically.